Publications by authors named "Deborah Berg"

Claim this Profile
P
Phase I/II Study of Subasumstat (TAK-981) in Combination With Rituximab in Relapsed/Refractory Non-Hodgkin Lymphoma.
Sarit E Assouline, Amitkumar Mehta, Walter Hanel, Stéphane Doucet, Patrick B Johnston, Deborah Berg

Clin Lymphoma Myeloma Leuk· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1b study of the anti-CD38 antibody mezagitamab in patients with relapsed/refractory multiple myeloma.
Amrita Y Krishnan, Krina K Patel, Meera Mohan, Sundar Jagannath, Ruben Niesvizky, Deborah Berg

Blood Neoplasia· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mezagitamab in systemic lupus erythematosus: clinical and mechanistic findings of CD38 inhibition in an autoimmune disease.
Scott R P McDonnell, Van Anh Nguyen, Noah M Walton, Carsten Merkwirth, Feng Hong, Deborah Berg

Lupus Sci Med· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized phase 3 study of ixazomib-dexamethasone versus physician's choice in relapsed or refractory AL amyloidosis.
Angela Dispenzieri, Efstathios Kastritis, Ashutosh D Wechalekar, Stefan O Schönland, Kihyun Kim, Deborah Berg

Leukemia· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2, open-label, multicenter study of ixazomib plus lenalidomide and dexamethasone in adult Japanese patients with relapsed and/or refractory multiple myeloma.
Shinsuke Iida, Tohru Izumi, Takuya Komeno, Yasuhito Terui, Takaaki Chou, Deborah Berg

Int J Clin Oncol· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.
Paul G Richardson, Shaji K Kumar, Tamás Masszi, Norbert Grzasko, Nizar J Bahlis, Deborah Berg

J Clin Oncol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical benefit of ixazomib plus lenalidomide-dexamethasone in myeloma patients with non-canonical NF-κB pathway activation.
Ajeeta B Dash, Jacob Zhang, Lei Shen, Bin Li, Deborah Berg

Eur J Haematol· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
c-MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide-dexamethasone in myeloma.
Alessandra Di Bacco, Nizar J Bahlis, Nikhil C Munshi, Hervé Avet-Loiseau, Tamás Masszi, Deborah Berg

Eur J Haematol· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance.
Shaji K Kumar, Jesus G Berdeja, Ruben Niesvizky, Sagar Lonial, Jacob P Laubach, Deborah Berg

Leukemia· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ixazomib maintenance therapy in newly diagnosed multiple myeloma: An integrated analysis of four phase I/II studies.
Meletios A Dimopoulos, Jacob P Laubach, Maria Asunción Echeveste Gutierrez, Norbert Grzasko, Craig C Hofmeister, Deborah Berg

Eur J Haematol· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Safety and management of adverse events of ixazomib/lenalidomide/dexamethasone therapy in Japanese patients with relapsed/refractory multiple myeloma].
Shinsuke Iida, Tohru Izumi, Nobuyuki Aotsuka, Takuya Komeno, Tadao Ishida, Deborah Berg

Rinsho Ketsueki· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Model-Informed Drug Development for Ixazomib, an Oral Proteasome Inhibitor.
Neeraj Gupta, Michael J Hanley, Paul M Diderichsen, Huyuan Yang, Alice Ke, Deborah Berg

Clin Pharmacol Ther· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association between response kinetics and outcomes in relapsed/refractory multiple myeloma: analysis from TOURMALINE-MM1.
Laurent Garderet, Jacob P Laubach, Anne-Marie Stoppa, Parameswaran Hari, Michele Cavo, Deborah Berg

Leukemia· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Healthcare resource utilization with ixazomib or placebo plus lenalidomide-dexamethasone in the randomized, double-blind, phase 3 TOURMALINE-MM1 study in relapsed/refractory multiple myeloma.
Parameswaran Hari, Huamao Mark Lin, Yanyan Zhu, Deborah Berg, Paul G Richardson

J Med Econ· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma.
Paul G Richardson, Craig C Hofmeister, Cara A Rosenbaum, Myo Htut, David H Vesole, Deborah Berg

Br J Haematol· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-reported health-related quality of life from the phase III TOURMALINE-MM1 study of ixazomib-lenalidomide-dexamethasone versus placebo-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma.
Xavier Leleu, Tamas Masszi, Nizar J Bahlis, Luisa Viterbo, Bartrum Baker, Deborah Berg

Am J Hematol· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients.
Hervé Avet-Loiseau, Nizar J Bahlis, Wee-Joo Chng, Tamas Masszi, Luisa Viterbo, Deborah Berg

Blood· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population Pharmacokinetic Analysis of Ixazomib, an Oral Proteasome Inhibitor, Including Data from the Phase III TOURMALINE-MM1 Study to Inform Labelling.
Neeraj Gupta, Paul M Diderichsen, Michael J Hanley, Deborah Berg, Helgi van de Velde

Clin Pharmacokinet· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone . placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1.
María-Victoria Mateos, Tamas Masszi, Norbert Grzasko, Markus Hansson, Irwindeep Sandhu, Deborah Berg

Haematologica· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma.
Shaji Kumar, Philippe Moreau, Parameswaran Hari, Maria-Victoria Mateos, Heinz Ludwig, Deborah Berg

Br J Haematol· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis.
Vaishali Sanchorawala, Giovanni Palladini, Vishal Kukreti, Jeffrey A Zonder, Adam D Cohen, Deborah Berg

Blood· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New developments in the management of relapsed/refractory multiple myeloma - the role of ixazomib.
Paul G Richardson, Shaji Kumar, Jacob P Laubach, Claudia Paba-Prada, Neeraj Gupta, Deborah Berg

J Blood Med· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disease burden of systemic light-chain amyloidosis: a systematic literature review.
Huamao Mark Lin, Xin Gao, Catherine E Cooke, Deborah Berg, Richard Labotka

Curr Med Res Opin· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treating Multiple Myeloma Patients With Oral Therapies.
Shaji K Kumar, Ravi Vij, Stephen J Noga, Deborah Berg, Lonnie Brent

Clin Lymphoma Myeloma Leuk· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Philippe Moreau, Tamás Masszi, Norbert Grzasko, Nizar J Bahlis, Markus Hansson, Deborah T Berg

N Engl J Med· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis